endometrial cancer Archives -

Merck & Co’s KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor

Keytruda encroaches on Jemperli’s endometrial cancer territory

https://pharmaphorum.com/news/keytruda-encroaches-on-jemperlis-endometrial-cancer-territory/

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for

NICE clears use of GSK’s Jemperli in endometrial cancer

https://pharmaphorum.com/news/nice-clears-use-of-gsks-jemperli-in-endometrial-cancer/

The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro,

FDA approves under-pressure GSK’s Jemperli for endometrial cancer

https://pharmaphorum.com/news/fda-approves-under-pressure-gsks-jemperli-for-endometrial-cancer/

Merck & Co’s conditional FDA approval for checkpoint inhibitor Keytruda in endometrial cancer looks secure, thanks to a

Merck gets confirmatory trial win for Keytruda in endometrial cancer

https://pharmaphorum.com/news/merck-gets-confirmatory-trial-win-for-keytruda-in-endometrial-cancer/

The combination of Merck & Co’s Keytruda with targeted drug Lenvima has been approved for endometrial cancer in

Merck, Eisai get triple approvals for Keytruda/Lenvima combination

https://pharmaphorum.com/news/merck-eisai-get-triple-approvals-for-keytruda-lenvima-combination/

endometrial cancer